Kamada Ltd. (KMDA)
KMDA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1567529/000121390026025934/0001213900-26-025934-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | KMDA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2013 |
| SEC CIK | 0001567529 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | L3 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $180.5M |
| Net income | $20.2M |
| Operating income | Not in SEC XBRL data |
| Net margin | 11.2% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | 22.0× |
| P/S (computed) | 2.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | F-3 | 2026-09-09 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-03-11 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-10-06 |
Source: SEC EDGAR submissions feed, 537 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.5% |
| 1 month | -5.9% |
| 3 months | +10.1% |
| Year to date | +7.8% |
| 1 year | +10.6% |
| From 52-week high | -18.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RZLT | Rezolute Inc. Common Stock (NV) | $4.61 | -5.34% | $445.9M |
| ARVN | Arvinas Inc. | $6.84 | -8.19% | $447.2M |
| NGNE | Neurogene Inc. Common Stock | $21.56 | -11.78% | $431.4M |
| PRTA | Prothena Corporation plc | $8.36 | -0.83% | $429.2M |
| OVID | Ovid Therapeutics Inc. | $2.19 | -9.13% | $427.7M |
| DMAC | DiaMedica Therapeutics Inc. | $7.82 | -4.63% | $421.7M |
| OCS | Oculis Holding AG | $7.62 | -3.30% | $469.3M |
| ALT | Altimmune Inc. | $2.43 | -5.08% | $472.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier